Form 4 for LLY Lilly (Eli)
Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-16 · accession 0000059478-23-000079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-21 | 2023-02-16 | LLY | Van Naarden Jacob | EVP, CEO Loxo@Lilly | M - OptEx | $0.00 | +2,785 | 13.2K | +27% | $0 |
| D | 2023-02-21 | 2023-02-16 | LLY | Van Naarden Jacob | EVP, CEO Loxo@Lilly | F - Tax | $335.01 | -1,314 | 11.8K | -10% | -$440.2K |
| D | 2023-02-21 | 2023-02-16 | LLY | Van Naarden Jacob | EVP, CEO Loxo@Lilly | M - OptEx | $0.00 | -2,785 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-16 | M | A | 2,785 | $0.00 | 13,159 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-16 | F | D | 1,314 | $335.01 | 11,845 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2023-02-16 | M | D | 2,785 | $0.00 | 0 | D | — · 2023-02-16 to 2023-02-16 | 2,785 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |